News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
The brand Magtein by Threotech has a sales value of approximately US $438 million
Subscribe To Our Newsletter & Stay Updated
